Drug profile

The FDA adverse-event record for Imidacloprid + Permethrin + N-Methylpyrolidone

253 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imidacloprid + Permethrin + N-Methylpyrolidone. See the species affected, top reactions, and outcomes below.

253
adverse-event reports
2.8%
death-coded share
Dog
most-reported species
53
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
253
Total Reports
7
Deaths Reported
2.8%
Death Rate

Active Ingredients

Imidacloprid + Permethrin + N-Methylpyrolidone

Administration Routes

TopicalUnknownOralCutaneousOther

Species Affected

Dog 251
Unknown 1
Cat 1

Most Affected Breeds

Retriever - Labrador 35
Retriever - Golden 14
Chihuahua 13
Crossbred Canine/dog 12
Dog (unknown) 10
Shih Tzu 9
Shepherd Dog - German 7
Pit Bull 7
Boxer (German Boxer) 7
Shepherd Dog - Australian 7

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 53
Lack of efficacy (ectoparasite) - flea 48
Emesis 45
Vomiting 40
Lack of efficacy - NOS 31
Other abnormal test result NOS 17
Behavioural disorder NOS 12
INEFFECTIVE, HOOKS 9
Not eating 8
Seizure NOS 8
Diarrhoea 8
Decreased appetite 8

Outcome Breakdown

Recovered/Normal
106 (42.1%)
Outcome Unknown
98 (38.9%)
Ongoing
31 (12.3%)
Recovered with Sequela
10 (4.0%)
Died
6 (2.4%)
Euthanized
1 (0.4%)

Imidacloprid + Permethrin + N-Methylpyrolidone Adverse Event Insights

253 reports name Imidacloprid + Permethrin + N-Methylpyrolidone; 7 recorded a death outcome (2.8% of reported events, not a population-level mortality rate). Active ingredient: Imidacloprid + Permethrin + N-Methylpyrolidone. Administration routes: Topical, Unknown, Oral, Cutaneous.

By species: Dog (251 reports), Unknown (1 reports), Cat (1 reports). By breed: Retriever - Labrador (35), Retriever - Golden (14), Chihuahua (13).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (53), Lack of efficacy (ectoparasite) - flea (48), Emesis (45), Vomiting (40). Outcome, 252 coded reports: Recovered/Normal leads at 42.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.